Anti-inflammatories for Genetic Diseases: 80.0% of denials overturned
In 5 California IMR decisions from 2007 to 2025, reviewers overturned 4 (80.0%). In the last five years: 100.0% of 4. 4 were medical-necessity disputes, 1 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2022 | 1 | 100.0% |
| 2025 | 3 | 100.0% |
What the findings mention
From recent overturned decisions
“The physician reviewer found that the parent of a patient has requested authorization and coverage for Duvyzat. Duvyzat (givinostat) is a U.S. Food and Drug Administration (FDA)-approved histone deacetylase inhibitor indicated for the treatment of ambulatory patients with Duchenne muscular dystrophy, regardless of specific gene mutations or exon-skipping eligibility. Unlike exon-skipping agents and gene therapy products, Duvyzat is mutation-agnostic and …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested authorization and coverage for Orladeyo. Orladeyo is indicated for the prophylaxis of hereditary angioedema (HAE) in patients with confirmed disease. Clinical guidelines support targeted therapy in patients with HAE due to C1 inhibitor dysfunction, particularly in those with recurrent or severe attacks. HAE is characterized by episodes …”
“Nature of Statutory Criteria/Case Summary: The parent of a patient has requested authorization and coverage for Orladeyo. Hereditary angioedema is a disabling disease for which early diagnosis and effective therapy are critical. All patients should have access to sufficient resources to control their hereditary angioedema symptoms and fulfill their potential at school, at work, and their relationships. In this case, …”
And one the reviewer upheld
“A 39-year-old female enrollee has requested the prescription medication Celebrex for treatment of her spastic paraparesis. Findings: The physician reviewer found that this patient has had progressive spasticity and pain due to diagnosed HSP. Numerous medications have been tried to manage her disruptive symptomatology. A combination of medications addressing spasticity, mood, fatigue and pain has been found most effective. Celebrex …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Anti-inflammatories denials for Genetic Diseases overturned?
In 5 California IMR decisions from 2007 to 2025, reviewers overturned 4 (80.0%). In the last five years: 100.0% of 4. 4 were medical-necessity disputes, 1 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.